Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/8/2018
SIETES contiene 92469 citas

 
 
 1 a 20 de 52 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Joseph A. FDA approves country’s first medicine made from marijuana. STAT Daily Recap 2018:2. [Ref.ID 102664]
2.Enlace a cita original Cita con resumen
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]
3. Cita con resumen
Gorelick DA. The effects of cannabis among adults with chronic pain. Ann Intern Med 2018;168:525. [Ref.ID 102602]
4.Enlace a cita original Cita con resumen
Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018;89:741-53. [Ref.ID 102555]
5. Cita con resumen
Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]
7.Tiene citas relacionadas Cita con resumen
Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]
8.Tiene citas relacionadas Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]
9.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
10. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
11.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]
12.Tiene citas relacionadas Cita con resumen
Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699. [Ref.ID 102018]
13. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
14.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
15.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
16. Cita con resumen
Anónimo. Brazil issues first license for sale of cannabis-based drug. DIA Daily 2017:1. [Ref.ID 101349]
18. Cita con resumen
Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]
19. Cita con resumen
Rubin R. Senators urge expedited evaluation of medical use of cannabidiol. JAMA 2016;316:13 de julio. [Ref.ID 100491]
Seleccionar todas
 
 1 a 20 de 52 siguiente >>